direct-acting antivirals

7 articles

  1. Gilead’s HCV drug sofosbuvir approved by the FDA but accessible for how many? Press Release – December 9 / Bangkok – Paris – Basel – London – New York

    On December 6, the U.S. Food and Drug Administration approved Gilead’s sofosbuvir (Sovaldi), an oral medication for the treatment of hepatitis C virus (HCV). Sofosbuvir and other direct-acting antivirals (DAAs) coming out of the drug development pipeline are more potent, have fewer side effects, (...) More

  2. Defuse hepatitis C, the viral time bomb: test and treat hepatitis C Position Paper for the 67th World Health Assembly, May 19–24, 2014